• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Global, regional, and national burden of neurological disorders during 1990 –2015: a systematic analysis for the Global Burden of Disease Study 2015
Publication date: Available online 17 September 2017 Source:The Lancet Neurology Author(s): GBD 2015 Neurological Disorders Collaborator GroupValery LFeiginAmanuel AlemuAbajobirKalkidan HassenAbateFoadAbd-AllahAbdishakur MAbdulleSemaw FeredeAberaGebre YitayihAbyuMuktar BeshirAhmedAmani NidhalAichourIbtihelAichourMiloud Taki EddineAichourRufus OlusolaAkinyemiSamerAlabedRajaaAl-RaddadiNelsonAlvis-GuzmanAzmeraw T.AmareHosseinAnsariPalwashaAnwariJohanÄrnlövHamidAsayeshSolomon WeldegebrealAsgedomTesfay MehariAteyLeticiaAvila-BurgosEuripideFrinelG. ArthurAvokpahoAleksandraBaracMiguelBarbozaSuzanne LBarker-ColloTillBärnighaus...
Source: The Lancet Neurology - September 19, 2017 Category: Neurology Source Type: research